| 书目名称 | Next-Generation Therapies and Technologies for Immune-Mediated Inflammatory Diseases |
| 编辑 | Paola Mina-Osorio |
| 视频video | |
| 概述 | The book describes why certain targets or technologies have not successfully made it into the clinic and what is needed to make that happen.The discussed technologies are at different stages in their |
| 丛书名称 | Progress in Inflammation Research |
| 图书封面 |  |
| 描述 | .As our understanding of immune mediated chronic inflammatory diseases (IMIDs) grows, it becomes more and more clear that these conditions result from the convergence of a multitude of pathogenic mechanisms whose relative individual contribution is different in different patient subsets..Promising new technologies have been conceived that address the hypotheses that targeting multiple pathways simultaneously, selectively delivering therapeutics to areas of inflammation and/or resetting the immune system, could take efficacy to new levels. However, we have long waited for the arrival of some of these technologies to the bedside, or even far enough in the drug development process in spite of the initial enthusiasm. Some of the examples covered in this book include bispecific antibodies and genomic medicines, microparticles and targeted delivery of drugs to inflamed vasculature..Most published reviews and book chapters on novel therapies for inflammatory diseases describe positive attributes of molecules or technologies under investigation and the rationale for developing them into therapeutics. The originality and potential value of this book is not in the description of these target |
| 出版日期 | Book 2017 |
| 关键词 | drug development; chronic inflammation; immunosuppressive microvesicles; genomic-based therapies; bi-spe |
| 版次 | 1 |
| doi | https://doi.org/10.1007/978-3-319-42252-7 |
| isbn_softcover | 978-3-319-82538-0 |
| isbn_ebook | 978-3-319-42252-7Series ISSN 1422-7746 Series E-ISSN 2296-4525 |
| issn_series | 1422-7746 |
| copyright | Springer International Publishing Switzerland 2017 |
发表于 2025-3-21 16:17:40
